白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2011年
3期
162-164
,共3页
武晓博%张巧花%侯淑玲%孙俊宁%贾莉%苏文%郭润莲
武曉博%張巧花%侯淑玲%孫俊寧%賈莉%囌文%郭潤蓮
무효박%장교화%후숙령%손준저%가리%소문%곽윤련
难治性淋巴瘤%T淋巴细胞亚群%杀伤细胞,天然
難治性淋巴瘤%T淋巴細胞亞群%殺傷細胞,天然
난치성림파류%T림파세포아군%살상세포,천연
Replased/Refratory lymphoma%T-lymphocyte subsets%Killer cells,natural
目的 探讨外周血T淋巴细胞亚群及自然杀伤(NK)细胞活性水平与难治性淋巴瘤的相关性.方法 采用流式细胞术(FCM)检测60例初治淋巴瘤患者化疗前外周血T淋巴细胞亚群水平与NK细胞的活性,化疗后随访分为难治组30例、有效组30例,以20名健康者为健康对照组.结果 淋巴瘤患者组化疗前外周血CD+4、CD+4/CD+8、NK细胞数比健康对照组低(30.17±8.63与46.52±1.39,t=12.218,P＜0.05;0.86±0.45与1.64±0.05,t=11.225,P＜0.05;12.39±7.08与19.29±0.84,t=6.365,P＜0.05),CD+3、CD+8细胞数比健康对照组高(76.14±10.71与70.48±1.44,t=-3.439,P＜0.05;40.28±14.03与28.35±0.73,t=-5.625,P＜0.05).难治组化疗前外周血CD+4、CD+4/CD+8、NK细胞数比有效组低(27.70±7.81与33.13±8.82,t=2.163,P=0.036;0.67±0.27与1.10±0.52,t=3.272,P=0.003;9.87±6.60与15.40±6.58,t=2.771,P=0.008),而CD+3、CD+8细胞数比有效组高(79.67±8.18与71.91±12.00,t=-2.540,P=0.015;44.70±13.99与34.98±12.41,t=-2.416,P=0.020).结论 淋巴瘤初治患者化疗前外周血T淋巴细胞亚群水平及NK细胞活性的检测,对判断、预测容易转归为难治的患者可能有一定的参考价值.
目的 探討外週血T淋巴細胞亞群及自然殺傷(NK)細胞活性水平與難治性淋巴瘤的相關性.方法 採用流式細胞術(FCM)檢測60例初治淋巴瘤患者化療前外週血T淋巴細胞亞群水平與NK細胞的活性,化療後隨訪分為難治組30例、有效組30例,以20名健康者為健康對照組.結果 淋巴瘤患者組化療前外週血CD+4、CD+4/CD+8、NK細胞數比健康對照組低(30.17±8.63與46.52±1.39,t=12.218,P＜0.05;0.86±0.45與1.64±0.05,t=11.225,P＜0.05;12.39±7.08與19.29±0.84,t=6.365,P＜0.05),CD+3、CD+8細胞數比健康對照組高(76.14±10.71與70.48±1.44,t=-3.439,P＜0.05;40.28±14.03與28.35±0.73,t=-5.625,P＜0.05).難治組化療前外週血CD+4、CD+4/CD+8、NK細胞數比有效組低(27.70±7.81與33.13±8.82,t=2.163,P=0.036;0.67±0.27與1.10±0.52,t=3.272,P=0.003;9.87±6.60與15.40±6.58,t=2.771,P=0.008),而CD+3、CD+8細胞數比有效組高(79.67±8.18與71.91±12.00,t=-2.540,P=0.015;44.70±13.99與34.98±12.41,t=-2.416,P=0.020).結論 淋巴瘤初治患者化療前外週血T淋巴細胞亞群水平及NK細胞活性的檢測,對判斷、預測容易轉歸為難治的患者可能有一定的參攷價值.
목적 탐토외주혈T림파세포아군급자연살상(NK)세포활성수평여난치성림파류적상관성.방법 채용류식세포술(FCM)검측60례초치림파류환자화료전외주혈T림파세포아군수평여NK세포적활성,화료후수방분위난치조30례、유효조30례,이20명건강자위건강대조조.결과 림파류환자조화료전외주혈CD+4、CD+4/CD+8、NK세포수비건강대조조저(30.17±8.63여46.52±1.39,t=12.218,P＜0.05;0.86±0.45여1.64±0.05,t=11.225,P＜0.05;12.39±7.08여19.29±0.84,t=6.365,P＜0.05),CD+3、CD+8세포수비건강대조조고(76.14±10.71여70.48±1.44,t=-3.439,P＜0.05;40.28±14.03여28.35±0.73,t=-5.625,P＜0.05).난치조화료전외주혈CD+4、CD+4/CD+8、NK세포수비유효조저(27.70±7.81여33.13±8.82,t=2.163,P=0.036;0.67±0.27여1.10±0.52,t=3.272,P=0.003;9.87±6.60여15.40±6.58,t=2.771,P=0.008),이CD+3、CD+8세포수비유효조고(79.67±8.18여71.91±12.00,t=-2.540,P=0.015;44.70±13.99여34.98±12.41,t=-2.416,P=0.020).결론 림파류초치환자화료전외주혈T림파세포아군수평급NK세포활성적검측,대판단、예측용역전귀위난치적환자가능유일정적삼고개치.
Objective To investigate the correlation of T cell subgroups and natural killer (NK) cell's activity level of peripheral blood of the patients with refractory lymphoma. Methods Flow cytometry was applied to detect T cell subgroups' level and NK cell's activity of peripheral blood in 60 early cure lymphoma patients with chemotherapy before and 20 normal controls , after chemotherapy follow-up they were divided into 30 cases of difficult cure group and 30 cases of effective group. Results Compared with the normal controls, CD+4, CD+4/CD+8 and NK cell in lymphoma patients with chemotherapy before decreased (30.17±8.63 vs 46.52±1.39, t =12.218, P ＜0.05; 0.86±0.45 vs 1.64±0.05, t =11.225, P ＜0.05; 12.39±7.08 vs 19.29±0.84,t =6.365, P＜0.05), while CD+3 and CD+8 cell increased (76.14±10.71 vs 70.48±1.44, t =-3.439, P＜0.05;40.28±14.03 vs 28.35±0.73, t =-5.625, P ＜0.05). Compared with effective group, CD+4 CD+4/CD+8 and NK cell in difficult response group with chemotherapy before decreased (27.70±7.81 vs 33.13±8.82, t =2.163, P =0.036;0.67±0.27 vs 1.10±0.52, t =3.272, P =0.003; 9.87±6.60 vs 15.40±6.58, t =2.771, P =0.008), while CD+3 and CD+8 cell increased (79.67±8.18 vs 71.91±12.00, t =-2.540, P =0.015; 44.70±13.99 vs 34.98±12.41, t =-2.416,P =0.020). Conclusion The detection of T cell subgroups' level and NK cell' s activity in early lymphoma patients before chemotherapy may play a role to diagnose and predict the outcome of refractory lymphoma patients.
